NCT06620302 2026-02-24Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar CarcinomaChildren's Oncology GroupPhase 1/2 Recruiting81 enrolled